AgingResearch.NewsJoin free

Nampt inhibitors

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Biotechnology and Biological Sciences Research Council and 4 more
  • Cells1

Outcomes

1

Axon survival

downin mammals cells1

1 study

  1. Nampt inhibitors protect against axon survival in mammals cells.

    “Inhibitors of NMN-synthesising enzyme NAMPT confer robust morphological and functional protection of injured axons and synapses despite lowering NAD.”

    Cellsinjured axons and synapses

    A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration

    Cell death and differentiation17 Oct 2014

Latest

Related